Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Mesía R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H, Cupissol D, De Raucourt D, Benasso M, Koralewski P, Delord JP, Bokemeyer C, Curran D, Gross A, Vermorken JB. Mesía R, et al. Ann Oncol. 2010 Oct;21(10):1967-1973. doi: 10.1093/annonc/mdq077. Epub 2010 Mar 24. Ann Oncol. 2010. PMID: 20335368 Free PMC article. Clinical Trial.
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
Licitra L, Mesia R, Rivera F, Remenár É, Hitt R, Erfán J, Rottey S, Kawecki A, Zabolotnyy D, Benasso M, Störkel S, Senger S, Stroh C, Vermorken JB. Licitra L, et al. Among authors: mesia r. Ann Oncol. 2011 May;22(5):1078-1087. doi: 10.1093/annonc/mdq588. Epub 2010 Nov 3. Ann Oncol. 2011. PMID: 21048039 Free PMC article. Clinical Trial.
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Vermorken JB, Peyrade F, Krauss J, Mesía R, Remenar E, Gauler TC, Keilholz U, Delord JP, Schafhausen P, Erfán J, Brümmendorf TH, Iglesias L, Bethe U, Hicking C, Clement PM. Vermorken JB, et al. Among authors: mesia r. Ann Oncol. 2014 Mar;25(3):682-688. doi: 10.1093/annonc/mdu003. Ann Oncol. 2014. PMID: 24567516 Free PMC article. Clinical Trial.
Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.
Vermorken JB, Psyrri A, Mesía R, Peyrade F, Beier F, de Blas B, Celik I, Licitra L. Vermorken JB, et al. Among authors: mesia r. Ann Oncol. 2014 Apr;25(4):801-807. doi: 10.1093/annonc/mdt574. Epub 2014 Feb 26. Ann Oncol. 2014. PMID: 24577117 Free PMC article.
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
Mesía R, Henke M, Fortin A, Minn H, Yunes Ancona AC, Cmelak A, Markowitz AB, Hotte SJ, Singh S, Chan AT, Merlano MC, Skladowski K, Zhang A, Oliner KS, VanderWalde A, Giralt J. Mesía R, et al. Lancet Oncol. 2015 Feb;16(2):208-20. doi: 10.1016/S1470-2045(14)71198-2. Epub 2015 Jan 15. Lancet Oncol. 2015. PMID: 25596660 Clinical Trial.
Late toxicity after radical treatment for locally advanced head and neck cancer.
Taberna M, Rullan AJ, Hierro C, Navarro V, Vázquez S, Lozano A, Vilajosana E, Maños M, Marí A, Viñals J, Mesía R. Taberna M, et al. Among authors: mesia r. Oral Oncol. 2015 Aug;51(8):795-9. doi: 10.1016/j.oraloncology.2015.05.002. Epub 2015 Jun 4. Oral Oncol. 2015. PMID: 26051499
152 results